Table 1—

Safety and tolerability of linezolid in patients treated for multidrug-resistant/extensively drug-resistant tuberculosis in Belarus, Germany, Italy and Switzerland, 2001–2007

Total600 mg q.d.600 mg b.i.d.p-value#
Patients
 Total n852857
 No adverse event50 (58.8)24 (85.7)26 (45.6)0.0004
 Any adverse event35 (41.2)4 (14.3)31 (54.4)0.0004
  Minor8 (9.4)08 (14)
  Major27 (31.8)4 (14.3)23 (40.4)0.01
Episodes
 Total n52547
 Anaemia23 (44.2)3 (60)20 (42.5)0.44
 Thrombocytopenia7 (13.5)0 (0)7 (14.9)
 Nausea/vomiting4 (7.7)1 (20)3 (6.4)0.25
 Polyneuropathy3 (5.8)1 (20)2 (4.3)0.13
 Others15 (28.8)0 (0)15 (31.9)
  • Data are presented as n (%), unless otherwise stated. #: comparison between 600 mg q.d. group and 600 mg b.i.d. group.